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ABSTRACT
Introduction: The objective of this study was to
assess the cost-effectiveness of the d-Nav Insulin
Guidance Service (Hygieia Inc.), a system
designed to improve glycemic control via the
use of insulin titration, in people with diabetes
at risk of developing neuropathic foot ulcers.
Methods: A Markov model containing four
health states (no ulcer, uninfected ulcer,
infected ulcer, and amputation) was developed
to compare d-Nav with current National Health
Service standard care. Patient movement
between the health states was governed by
event rates taken from the wider literature.
Both the healing rate for uninfected ulcers and
the rate of recurrence for uninfected ulcers were
directly influenced by the patient’s glycated
hemoglobin (HbA1c). Separate mean HbA1c
values were assigned to treatment and control
patients and taken from a single-arm study that
examined the effect of d-Nav on the outcomes
of 122 patients, with HbA1c for control patients
based on values recorded in the 12-month
period prior to the study and HbA1c for d-Nav
based on values recorded during the trial.
Weekly cycles were applied, and patient
resource use and quality-adjusted life years
(QALYs) were estimated over a 3-year time
horizon. Univariate sensitivity analysis was
undertaken.
Results: In the base case, d-Nav was cost-saving
and produced more QALYs than standard care,
with a total net monetary benefit value of £1459
per patient. Univariate analysis indicated that
the model results are relatively robust to
variations in underlying parameters, with
patient HbA1c having the most significant
impact on outcomes.
Conclusion: Interventions that aim to improve
glycemic control, such as d-Nav, appear to be a
cost-effective use of healthcare resources when
targeted at those with poor glycemic control at
high risk of developing foot ulcers.
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INTRODUCTION
The major consequence of poor glycemic
control in people with diabetes is chronic
hyperglycemia [1], which can lead to a large
number of microvascular and macrovascular
issues. One common microvascular condition
is foot ulceration, which results from diabetic
neuropathy and vascular complications. The
risk of developing neuropathy is directly
proportional to both the duration and
magnitude of hyperglycemia [2], and
therefore, maintaining glycemic control is
vital to reduce the number of foot ulcers.
There are mixed data on the prevalence of foot
ulcers, but estimations as high as 25% of
patients with diabetes being affected over their
lifetime, have been made [3]. The management
of the condition is complex as a large
proportion will fail to heal, and there is an
increased risk of serious infection and extremity
amputation [4]. Therefore, the condition is a
significant financial burden on the National
Health Service (NHS), through outpatient costs,
increased bed occupancy and prolonged
hospital stays [5]. The size of this burden is
highlighted by a report by Hex and colleagues
[6], who estimated the cost of foot ulcers and
amputations to the NHS to be £985 m in
2010/2011, the most expensive category of
diabetes complications.
There is a well-established link between
uncontrolled or high glycated hemoglobin
(HbA1c) levels and clinical complications [7].
As such, it is important to keep HbA1c levels
stable to reduce the risk of these complications,
with guidance in the UK stating that HbA1c
should be kept at a level of 6.5% (48 mmol/mol)
or below in people with type 1 diabetes, and
between 6.5% and 7% (48–53 mmol/mol) in
people with type 2 diabetes [8, 9]. However, in
practice, patients often fail to achieve
suitable HbA1c levels, as shown by a survey in
Sweden that found only less than one-third of
insulin-treated patients with type 2 diabetes to
havereached the recommended HbA1c goal of
\7% (53 mmol/mol), over 6 years [10]. Overall,
there is mixed evidence regarding the mean
HbA1c level among the diabetes population.
However, two large-scale meta-analyses of
diabetes-related interventions found that,
among participants, baseline HbA1c was 8.05%
and 8.13%, indicating that mean levels are
likely to be at least 8% (64 mmol/mol) [11, 12].
Insulin therapy is seen as an important
treatment option for both type 1 and type 2
diabetes [13, 14]. Administration is commonly
achieved via manual insulin injection or insulin
pumps, supported by self-monitoring of blood
glucose. However, this method has been used
for many years, and the problem of poor
glycemic control remains. This issue is
highlighted by a paper by Simmons and
colleagues [15], which found that 63% of
pump users (916 participants) and 70% of
injection users (978 participants) had a HbA1c
of 8.5% (69 mmol/mol) or greater. More
effective glycemic control can be achieved
using an insulin titration protocol. These
protocols allow for more sensitive adjustments
in insulin doses, leading to both near-normal
glucose readings and the avoidance of
hypoglycemic events [16]. However, insulin
titration is complex, so achieving these goals
is a difficult task. The difficulty largely arises as
adjustments to insulin dosage must currently be
undertaken with the assistance of a physician.
However, visits usually occur every 3–6 months,
making the system of titration unresponsive to
short-term changes in blood glucose. Bastyr and
colleagues [17] analyzed the impact of intensive
insulin therapy, accompanied by monitoring
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using an electronic diary. The study found that
HbA1c fell over the 26-week investigation
period, in line with similar trials. The study
also found that a mean number of 98.5 insulin
adjustments per patient year were required for
patients with type 1 diabetes, and 112.5
required for patients with type 2 diabetes.
These adjustments were largely
clinician-driven, indicating the high levels of
resource use required [17].
To overcome this problem, the Diabetes
Insulin Guidance Service (DIGSTM, Hygieia
Inc.) has been developed. This service aims to
optimize patients’ insulin dosage regimens. This
is achieved through the use of algorithms that
identify patterns in time-lagged glucose
readings and adjust insulin dosage
accordingly. DIGS is operational via a
handheld device, known as d-Nav (Hygieia
Inc.), which also includes an in-built glucose
sensor (see Fig. 1). Because this process is
automated, it facilitates the unsupervised
alteration of insulin dosage [16]. Therefore,
suitable patients can be prescribed a d-Nav
device to use on a daily basis to control their
insulin regimen. As d-Nav aims for more
sensitive adjustments in insulin, this should
lead to improved glycemic stability, particularly
in patients with high HbA1c levels. The device
is supported by a nurse-based service to ensure
that d-Nav is being used correctly, with
communication possible both in person and
by phone. Patient readings are also saved on an
online database that can be reviewed by the
patient’s regular physician to ensure that the
service is linked to the wider healthcare system.
In this paper, the cost-effectiveness of the
d-Nav service for patients with poor glycemic
control is evaluated from the perspective of the
UK NHS. The d-Nav service is compared with
current standard care in which patients do not
have access to the d-Nav service and, therefore,
any adjustments to their insulin regimen must




The target population for this analysis was
patients with diabetes currently treated by the
UK NHS who are at high risk of foot ulcers,
defined as those who have a HbA1c of 9% or
greater (74.9 mmol/mol). HbA1c is the main
driver as it has been established that it directly
influences both the healing rate for foot ulcers
and the rate of wound recurrence [18, 19]. Two
patient groups were included: those receiving
d-Nav to control HbA1c (i.e., the treatment
group), and those receiving current standard
NHS diabetes care (i.e., the control group). For
this analysis, NHS standard care is defined as the
administration of insulin via injection or
pumps and accompanied by self-monitoring of
blood glucose. In practice, patients with
Fig. 1 Example of d-Nav device. The Diabetes Insulin
Guidance System has been designed to optimize patients’
insulin dosage regimens through the use of algorithms that
identify patterns in time-lagged glucose readings and adjust
insulin dosage accordingly. This is achieved using a
handheld device (d-Nav), which is shown here, and is
supported by a nurse-based service to ensure good use
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diabetes would receive a greater range of
therapies, but this distinct population has
been chosen here, as these are the patients
most applicable to the d-Nav service. The
underlying HbA1c for patients in both groups
was determined by a single-arm observational
study, which examined the effectiveness of
d-Nav to improve glycemic control [20]. This
was a single-center evaluation in which 122
patients were trained to use d-Nav as part of
their usual treatment protocol and, then,
followed for 12 months, with the primary
outcome measures being change in HbA1c.
Ninety-four patients completed the full
12-month service evaluation. HbA1c was also
investigated in all patients in the 12 months
prior to study initiation and remained
stable throughout. At study initiation, the
mean HbA1c was 9.2 ± 1.4%. During the
study, mean HbA1c decreased to 7.8 ± 1.2% at
3–5 months and, further, to 7.5 ± 1.2% at
6–12 months.
It was assumed that throughout the period of
the analysis, d-Nav patients had a stable HbA1c
that was equivalent to patients at the end of the
study period (i.e., 7.5 ± 1.2%), while control
patients had a stable HbA1c that was equivalent
to patients at study baseline (i.e., 9.2 ± 1.4%). In
reality, over the long term, d-Nav may reduce
HbA1c further, as shown in Fig. 2. Three year data
has recently been presented by Dr Harper and
colleagues at the 2016 American Diabetes
Association conference, which confirmed that
HbA1cwithd-Nav remained stable at 7–7.5%over
three years [21]. This data was presented after this
analysis was completed, and therefore, the data
were not formally included. To more accurately
model the glycemic level of patients, these mean
and standard deviation values were used to
estimate the distribution of patients across six
HbA1c levels (\6%, 6–7%, 7–8%, 8–9%, 9–10%,
and[10%). A normal distribution was assumed.
The number of patients in each level, for both the



































No. of patients N=34
Average HbA1c 6.99%
Standard deviation 0.84%
Fig. 2 Subscribers on d-Nav service for 27? months. All
UK-based users of the d-Nav service have their HbA1c
levels recorded as part of their treatment regimen. The
results of 34 patients who have recorded data for at least
27 months are presented here (data provided by Hygieia
Inc., the manufacturer of the device). It shows that over
the long term, d-Nav users have a mean HbA1c of less
than 7%
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Patients are removed from the d-Nav service
if their HbA1c levels do not reduce after the first
3 months, as it is deemed that they are not
benefiting. It was assumed that the proportion
of patients with a HbA1c of C9%, as determined
by the underlying HbA1c distribution for d-Nav
patients, would stop at month three. This
equated to 10.56% of d-Nav patients, and, in
the model, these patients incurred the cost of
d-Nav for the first 3 months and then reverted
to control group costs for the remaining time in
the model.
Model Structure
The cost-effectiveness of d-Nav was determined
using a Markov model (Fig. 4), which was
constructed using Microsoft Excel (Microsoft
Corporation, Redmond, WA, USA). Markov
models are commonly used in economic
evaluations to model long-term patient
outcomes and are particularly applicable for
progressive chronic conditions such as diabetes.
Within Markov models, patients are allocated to
predefined health ‘states’, with each state
associated with specific costs and health
outcomes. The current model contained four
health states: no ulcer, uninfected ulcer,
infected ulcer and amputation. Markov models
operate in cycles, which cover a discrete time
period (e.g., 1 month, 1 year), with weekly
cycles adopted here. Patients remain in a set
health state for one cycle and can transition to a
separate state at the end of each cycle.
Transition probabilities are used to predict
patient movement between health states; for
example, if a patient is treated with a more
efficacious intervention, they will have a lower




<6% 6 - 7% 8 - 9%7 - 8% 9 - 10% >10%
Fig. 3 Distribution of patients by HbA1c level. Within
the analysis, patient HbA1c levels impact on the healing
rate for diabetic foot ulcers, with higher HbA1c levels
associated with lower rates of healing. The distribution of
d-Nav and standard care patients across six HbA1c
categories is presented below. The distribution is based
on mean and standard deviation HbA1c values recorded
by Donnelly et al. [20]
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probability of transitioning from a better to a
worse health state. As patients accumulate costs
and health outcomes associated with the states,
they reside in overtime, then remaining in a
better health state leads to fewer costs and
improved health outcomes.
In the currentmodel, patients started in either
the ‘no ulcer’ or ‘uninfected ulcer’ state. The
distribution of patients between these two states
was determined by the underlying prevalence of
foot ulcers. It has been established that the
prevalence of foot ulcers is 4.8% across the
whole diabetes population, and this value
increases to 12.8% for patients aged 65 and over
[22]. These figures cover all patients with
diabetes, including those who have good
glycemic control. It is, therefore, reasonable to
assume that prevalence will be greater in the
high-risk population considered in this analysis.
However, an exact value for this parameter could
not be identified. As such, a conservative
assumption of 15% was adopted, and variations
to this parameterwere assessed during sensitivity
analysis. Patients could move between the
different states as outlined in Fig. 4. Once






























Standard care model 
Fig. 4 Outline of Markov model structure. A Markov
model was adopted to predict long-term patient outcomes
with d-Nav and standard care. To capture the impact of
diabetic foot ulcers on healthcare system costs and patient
outcomes, four health states were included in the model:
healed ulcer, unhealed ulcer, infected ulcer and
amputation. The amputation state was absorbing such
that once patients enter this state, they remained there for
the full time horizon. Speciﬁc costs and health outcomes
were allocated to each health state. The model structure
and transition probabilities for each treatment option are
shown
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assumed that they would remain in that state for
the remainder of the time in the model. In total,
the model covered a 3-year time period, and this
length of time was chosen due to the transient
nature of foot ulcers. Within this 3-year period,
mortalitywouldbenegligiblewithnodiscernible
difference between treatment groups expected.
Therefore, mortality was not considered.
Transition Probabilities
Movement between the health states was
governed by transition probabilities, which
were taken from the wider literature (Table 1).
Due to the short timeframe used, these
probabilities were not time-dependent. HbA1c
directly influences both the healing rate and the
rate of wound recurrence for foot ulcers.
Christman et al. [18] stratified 183 individuals
with diabetes into three HbA1c groups (\7%,
7–8%, and[8%) and investigated the change in
wound area (cm2 per day). The investigators
found that, for each 1% point increase in
HbA1c, daily change in wound area decreased
by 0.022 cm2 (P = 0.027). They concluded that
glycemic control is directly correlated with the
healing rate for foot ulcers. In the model, daily
change in wound area was converted to daily
healing rate by dividing the change in area by
the baseline area size for each of the three
HbA1c categories. These healing rates were then
converted to weekly transition probabilities,
using the equation outlined in Fig. 5 and
applied to each of the six HbA1c levels
discussed previously. The HbA1c categories
used in the model did not perfectly match
those assessed by Christman et al. [18].
Therefore, the healing rate for patients with
HbA1c\7% was applied to both\6% and 6–7%
patients, while the healing rate for patients with
HbA1c[8% was applied to 8–9%, 9–10%, and
[10% patients.
Dubsky´ et al. [19] followed 73 patients with
diabetes over a 3-year time period to examine
the frequency of, and risk factors for, foot ulcer






HbA1c\6% 3.24% 0.206 [18]
HbA1c 6–7% 3.24% 0.206 [18]
HbA1c 7–8% 3.24% 0.206 [18]
HbA1c 8–9% 2.06% 0.135 [18]
HbA1c 9–10% 0.68% 0.047 [18]
HbA1c[10% 0.68% 0.047 [18]
Rate of wound recurrence
HbA1c\7.5% 33.3% N/A [19]
HbA1c[7.5% 67.3% N/A [19]
Rate of wound recurrence
Treatment 50.30% 0.0045 Calculated









No ulcer 0.600 N/A [26]
Uninfected ulcer 0.465 N/A [26]
Infected ulcer 0.465 N/A [26]
Amputation 0.450 N/A [26]
A number of input parameters were utilized in the model
to predict long-term patient outcomes. These parameters
are summarized below, along with the source of the
information. Where applicable, rates were converted to
probabilities to make the data applicable to the model
structure adopted for the analysis. Both the original rate
and subsequent transition probability are presented
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recurrence, with HbA1c being significantly
associated with the risk of ulceration
recurrence. Using data from the paper by
Dubsky´ et al. [19], it was estimated that the
3-year risk of recurrence was 33.3% for patients
with HbA1c\7.5% and 67.3% for patients with
HbA1c[7.5%. These rates were applied to the
patient distributions to generate predicted
3-year healing rates. To be suitable for the
Markov model, these healing rates were also
converted to transition probabilities (Fig. 5).
Rate of infection, healing rate for infected
ulcers and risk of amputation were also
required. These parameters were not linked to
patient HbA1c due to a deficiency in relevant
data from the wider literature. Therefore,
transition probabilities were estimated from
relevant values identified in a targeted
literature search and applied equally across all
HbA1c groups.
Costs and Resource Use
Where necessary, costs were inflated to 2013/14
prices using the hospital and community health
services index [23]. The insulin regimen
considered in this analysis is once-daily
long-acting insulin and short-acting insulin
with meals, as it is the regimen most
commonly used by d-Nav patients. Daily
insulin usage was based on unpublished data
from the observational d-Nav study. Overall,
insulin usage was significantly higher in d-Nav
patients. A large number of oral anti-diabetic
agents were also included within the model.
With d-Nav, patients are not required to take
any agents except for insulin and metformin
and, also, do not require the use of a blood
glucose monitoring device as glucose tests are
conducted with d-Nav. Therefore, total usage
for glucose test strips and all anti-diabetic
agents, except metformin, remained at zero for
the treatment group. Usage among the control
group was determined using data from the
Northern Irish South Eastern Health and Social
Care Trust. The Trust provided data on
anti-diabetic agent usage from a sample of
3665 patients with type 2 diabetes (see
Table 2). It was assumed that 100% of control
group patients used a blood glucose monitoring
device, in line with the patient population
deemed most applicable for d-Nav, and they
self-tested, on average, three times per day at a
mean cost of £14.57 for 50 test strips [24]. This
was combined with an average cost of £3.42 for
100 lancets equating to a weekly cost of £6.84
[25]. The cost of the d-Nav service is altered
depending on the total number of users within
each population, as outlined in Table 3.
Patients also incurred costs depending on
the health state within which they resided
(Table 3). These health state costs were sourced
from the literature [4] and applied to weekly
cycles.
Utility
To estimate the impact of treatment on patient
health-related quality of life, quality-adjusted
life year (QALY) scores were calculated using
utility values. Utility is a measurement of
patient’s preferences for different health
p = 1 – eLn(1-r/t)
where: p is the transition probability
r is the event rate
t is the time period
Fig. 5 Equation for converting event rates to transition
probabilities. Event rates, such as the rate of ulcer healing,
must be converted to probabilities to be applicable to
Markov models. Within the analysis, rates were converted
to probabilities using the equation outlined below
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outcomes. It uses a cardinal scale in which zero
represents death and one represents full health.
Utility values can be combined with estimates
of survival, to calculate QALY scores, which
combine both morbidity and mortality into a
single outcome measure. A QALY score of one is
equivalent to 1 year of life in full health. QALYs
enable a consistent measurement of health
benefit across different treatment options. This
is particularly applicable when a new treatment
option is expected to generate extra health
benefits compared to current standard care but
at a greater cost. In the analysis, utility values
were based on the four health states. Values
were sourced from the literature and applied to
each weekly cycle [26]. To generate the QALY
values, cumulative utility scores were divided by
the total number of weeks elapsed.
Sensitivity Analysis
To test uncertainty within the model,
univariate sensitivity analysis was undertaken.
Underlying parameter values were varied to
examine the impact on model outputs, as
measured by net monetary benefit. For the
majority of parameters, the original value was
altered by ±50% to robustly examine the effects
of changes. Utility scores for all health states,
and mean HbA1c for both treatment and
control patients, were varied within smaller
ranges as ±50% was deemed to generate
unrealistic values. The extreme values (high
and low) tested for each parameter are shown in
Fig. 6. Two cases of scenario analyses were also
undertaken. First, the impact of incorporating
only those patients with foot ulcers was
examined (i.e., all patients started the model
in the uninfected state, and this equated to 15%
of the overall cohort). Second, a scenario was
created in which the distribution of control
patients’ HbA1c levels was fixed, so that all
patients had a HbA1c of C9%. This is the
optimal population to be targeted with the
intervention.
Evaluation
Costs and utility values used in the model
were both discounted at a rate of 3.5%, in line
























Patients with diabetes may be treated with an anti-diabetic
agent. In clinical practice, as part of the d-Nav service, all
patients are required to use metformin but no other
anti-diabetic agent. The values presented in the table show
the numbers and proportion of patients in the standard
care receiving each of the oral anti-diabetic agents. These
values were taken from a sample of drug usage for 3665
patients with type 2 diabetes with data provided by South
Eastern Health and Social Care Trust. The proportion of
patients receiving each drug was applied to standard care
patients in the analysis
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Table 3 Resource use and health state costs
Parameter Weekly cost Source
Health states
No ulcer £5.21 [4]
Uninfected ulcer £463 [4]
Infected ulcer £460 [4]
Amputation £818 [4]
d-Nav Service
Installation fee £102.17 Communication with service provider
Service fee
0–50 users £44.96 Communication with service provider
51–100 users £40.46 Communication with service provider
101–200 users £36.67 Communication with service provider



















Lantus (long-acting) £30.68 per 1000 units [30]
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with guidance issued by the National Institute
for Health and Care Excellence (NICE) for its
technology appraisal program [27]. To
determine the cost-effectiveness of the
treatment from a societal perspective, a
willingness-to-pay threshold was adopted.
Within the model, a cost per QALY
threshold of £20,000 was applied, the lower
value of the range formally adopted by NICE
[27]. This threshold was used to generate net
monetary benefit values with positive values
indicating cost-effectiveness at the chosen
threshold.
Compliance with Ethics Guidelines
The analysis in this article is based on
previously conducted studies and does not
Table 3 continued
Parameter Weekly cost Source
Apidra (short-acting) £16.00 per 1000 units [30]
Humulin M3 (biphasic) £15.68 per 1000 units [30]
Blood glucose monitoring £6.84 [24, 25]
All costs that have been applied within the analysis are summarized in the table, with the original source also given. All costs
are weekly and per patient
-£5,000 -£4,000 -£3,000 -£2,000 -£1,000 £0 £1,000 £2,000 £3,000 £4,000 £5,000
Ulity of amputaon (0.36; 0.54)
Ulity of infected ulcer (0.375; 0.575)
Ulity of uninfected ulcer (0.375; 0.575)
Risk of amputaon (0.04; 0.13)
Ulity of no ulcer (0.48; 0.72)
Drop-out rate - d-Nav (0.0525; 0.1575)
Cost of amputaon (400; 1200)
Prevalence of foot ulcers - high risk (0.075; 0.225)
Probability infecon heals (0.04; 0.12)
Wound recurrence - <7.5% (0.16; 0.5)
Risk of infecon (0.09; 0.27)
Cost of infected foot ulcer (220; 680)
Cost of uninfected foot ulcer (230; 690)
Paent HbA1c - d-Nav (6; 9)
Paent HbA1c - SC (7; 10.5)
Net Monetary Benefit
Low Parameter Value High Parameter Value
Fig. 6 Tornado diagram of univariate sensitivity analysis.
Tornado diagrams can be used to summarize the results of
univariate sensitivity analysis. During univariate analysis,
the value of each model parameter is individually altered
within a predeﬁned range to see the impact on results as
measured by the net monetary beneﬁt value. Each
parameter is listed on the left, with the extreme values
(low and high), that were tested, shown in brackets. The
y-axis represents the base-case analysis. The impact of
changes in individual parameter values on the net
monetary beneﬁt is shown by the individual bars. If a
bar crosses the £0 threshold, it indicates that d-Nav is no
longer cost-effective at the parameter value adopted. The
graph indicates that three parameters alter the model
outputs such that d-Nav is no longer cost-effective. The
remaining 12 parameters have no impact
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involve any new studies of human or animal
subjects performed by any of the authors.
RESULTS
In the analysis, d-Nav was estimated to be cost
saving (-£1278) and produced more QALYs
(0.009) than standard care with a total
monetary net benefit value of £1459 per
patient.
The univariate sensitivity analysis is
summarized in Fig. 6. The parameter with the
largest impact on results was the underlying
mean HbA1c of both d-Nav and standard care
patients. During univariate analysis, the net
monetary benefit became negative, indicating
that d-Nav is no longer cost-effective, when the
mean HbA1c value for d-Nav patients increased
from 7.5% (59 mmol/mol) to 8.2%
(66 mmol/mol), indicating that d-Nav is
cost-effective at all values lower than 8%
(64 mmol/mol). Similarly, the net monetary
value became negative when the mean HbA1c
for standard care patients decreased from 9.2%
(77 mmol/mol) to 8.7% (72 mmol/mol). Two
other parameters also affected the choice of
optimal treatment strategy, as determined by
the net monetary benefit value, during
univariate sensitivity analysis. When the rate
of wound recurrence for patients with HbA1c
[7.5% decreased from 67.30% to 52.00%, and
also when the weekly cost of an uninfected foot
ulcer decreased from £463 to £230, the net
monetary benefit value became negative.
For the scenario analysis, when the scenario
was adopted in which all patients started the
model in the uninfected foot ulcer state (15% of
the baseline cohort size), then the net monetary
benefit increased substantially to £5169. This
equates to per-patient savings of £4858 and
QALY gains of 0.016. Similarly, when the
scenario was adopted in which all standard
care patients started the model with a HbA1c
level of C9%, the net monetary benefit value
again increased substantially to £5310. This
equates to savings of £4992 per patient and
QALY gains of 0.016.
DISCUSSION
This analysis indicates that patients with
diabetes who have abnormal HbA1c
measurements should be targeted with
interventions that may improve glycemic
control, such as d-Nav, as they appear to
provide value for money. Moreover, as
highlighted by the scenario analysis,
interventions that specifically target patients
with very high HbA1c (i.e.,[9%) or those who
are already with a foot ulcer, are likely to lead to
improved patient outcomes and greater cost
savings. Treatments that improve glycemic
control are estimated to be cost-effective due
to the reduction in the incidence of foot ulcers
and amputations. This leads to savings as fewer
resources are required to treat the underlying
conditions. Furthermore, there is a reduction in
the number of prescriptions for anti-diabetic
agents and blood glucose monitoring devices
and test strips and an improvement in patient’s
quality of life. Given the scale of the burden
caused by diabetic foot ulcers, implementing
interventions, such as d-Nav, has the potential
to generate substantial benefits to the
healthcare system. It is important to note that
this analysis focused solely on outcomes
relating to foot ulcers. However, by improving
glycemic control, patients with diabetes and the
wider healthcare system are also likely to benefit
from a reduction in the incidence of other
diabetic complications (e.g., stroke,
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retinopathy), and the magnitude of these
benefits could be significant.
Based on the sensitivity analysis that was
undertaken, the model results appear to be
relatively robust to changes in underlying
parameters. The results are most sensitive to
changes in the patient HbA1c, which is
unsurprising as the model outcomes are
largely driven by the reduction in HbA1c
facilitated by d-Nav. This also indicates that
interventions are best targeted at patients with
very high ([9%) HbA1c levels.
The HbA1c values, which are the main
drivers of the model, are taken from a
single-arm study. Ideally, HbA1c would be
based on a large-scale, randomized trial that
quantifies the difference in HbA1c between
patients using standard care and those
enrolled on the d-Nav service. However, in
this instance, the lack of a control group
should not be considered a major limitation,
because it is reasonable to use patient HbA1c at
study baseline as the value used for the control
group in the model. This is because the value
adopted in the analysis is representative of the
wider, high-risk population that should be
targeted with interventions to improve
glycemic control.
The second limitation with the model is
that, within the control group, it is assumed
that the mean HbA1c remains at [9%
throughout the full time horizon. In reality,
some patients may show improvement;
particularly if their treatment regimen is
altered (e.g., they are moved onto continuous
blood glucose monitoring). However, in clinical
practice, a large number of patients will not
alter their lifestyle or treatment and, therefore,
are likely to remain with unstable HbA1c levels.
It is these patients that d-Nav should be targeted
at and the ones that are considered in this
analysis.
Although the association between HbA1c
and diabetic complications is well established,
there appears to be a deficit in the research that
has been undertaken to quantify the
relationship between glycemic control and
neuropathy. Therefore, HbA1c could not be
linked to the rate of infection, the healing rate
for infected ulcers, or the rate of amputation;
following a targeted literature search. In reality,
patients with HbA1c within recommended
ranges are likely to have lower rates for each
of these parameters and, thus, improved
outcomes overall. It is, therefore, unfortunate
that this link could not be quantified in this
analysis, and more clinical evaluations are
needed to rectify the issue. Furthermore, a
target review of the literature was undertaken,
and while comprehensive, it may not have
captured all available evidence. Therefore, a
formal systematic literature review would
strengthen the analysis if undertaken.
CONCLUSIONS
The analysis undertaken here indicates that
interventions targeted at patients with diabetes
with poor glycemic control, such as d-Nav, may
be cost-effective in the prevention and
management of neuropathic foot ulcers.
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